
Michael Brainin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1611426/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	COVID-19-related delays of botulinum toxin injections have a negative impact on the quality of life of patients with dystonia and spasticity: a single-center ambulatory care study. Journal of Neural Transmission, 2022, 129, 49-53.	1.4	5
2	Primary stroke prevention worldwide: translating evidence into action. Lancet Public Health, The, 2022, 7, e74-e85.	4.7	156
3	World Stroke Organization (WSO): Global Stroke Fact Sheet 2022. International Journal of Stroke, 2022, 17, 18-29.	2.9	649
4	Role and Impact of Cerebrolysin for Ischemic Stroke Care. Journal of Clinical Medicine, 2022, 11, 1273.	1.0	12
5	Polypill: Benefits Seen for Stroke and Other Outcomes. Stroke, 2022, 53, 2695-2701.	1.0	5
6	Conceptual framework for establishing the African Stroke Organization. International Journal of Stroke, 2021, 16, 93-99.	2.9	20
7	Polypills for stroke prevention: they work and are effective. European Journal of Neurology, 2021, 28, 3879-3880.	1.7	0
8	The African Stroke Organization — a new dawn for stroke in Africa. Nature Reviews Neurology, 2021, 17, 127-128.	4.9	7
9	Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial. Circulation, 2021, 144, 1738-1746.	1.6	31
10	C-REGS 2 - Design and methodology of a high-quality comparative effectiveness observational trial. Journal of Medicine and Life, 2021, 14, 700-709.	0.4	1
11	The global burden of neurological disorders: translating evidence into policy. Lancet Neurology, The, 2020, 19, 255-265.	4.9	377
12	Tracking the global burden of stoke and dementia: World Stroke Day 2020. International Journal of Stroke, 2020, 15, 817-818.	2.9	10
13	WSO and WHF joint position statement on population-wide prevention strategies. Lancet, The, 2020, 396, 533-534.	6.3	21
14	Comparison of oral glucose tolerance test and HbA1c in detection of disorders of glucose metabolism in patients with acute stroke. Cardiovascular Diabetology, 2020, 19, 204.	2.7	5
15	Antithrombotic Treatment of Embolic Stroke of Undetermined Source. Stroke, 2020, 51, 1758-1765.	1.0	23
16	Global prevention of stroke and dementia: the WSO Declaration. Lancet Neurology, The, 2020, 19, 487-488.	4.9	61
17	International Impact of <i>Stroke</i> . Stroke, 2020, 51, 1036-1039.	1.0	0
18	What Is the Best Mix of Populationâ€Wide and Highâ€Risk Targeted Strategies of Primary Stroke and Cardiovascular Disease Prevention?. Journal of the American Heart Association, 2020, 9, e014494.	1.6	31

#	Article	IF	CITATIONS
19	COVID-19 and stroke—A global World Stroke Organization perspective. International Journal of Stroke, 2020, 15, 361-364.	2.9	314
20	Approaches to global stroke care during the COVID-19 pandemic. Stroke and Vascular Neurology, 2020, 5, 107-109.	1.5	10
21	Fixed-dose combination antihypertensive medications. Lancet, The, 2019, 394, 637-638.	6.3	44
22	Cerebral Small-Vessel Disease. , 2019, , 202-212.		0
23	World Stroke Organization (WSO): Global Stroke Fact Sheet 2019. International Journal of Stroke, 2019, 14, 806-817.	2.9	249
24	Poststroke Cognitive Recovery Prediction. Stroke, 2019, 50, 2647-2647.	1.0	0
25	Reducing the burden of stroke: Opportunities and mechanisms. International Journal of Stroke, 2019, 14, 761-762.	2.9	9
26	Multi-level community interventions for primary stroke prevention: A conceptual approach by the World Stroke Organization. International Journal of Stroke, 2019, 14, 818-825.	2.9	14
27	Priorities to reduce the burden of stroke in Latin American countries. Lancet Neurology, The, 2019, 18, 674-683.	4.9	102
28	Standards of Practice in Acute Ischemic Stroke Intervention International Recommendations. Canadian Journal of Neurological Sciences, 2019, 46, 269-274.	0.3	3
29	Stroke epidemiology in China: which are the next steps?. Lancet Neurology, The, 2019, 18, 325-326.	4.9	3
30	São Paulo call to action for the prevention and control of high blood pressure: 2020. Journal of Clinical Hypertension, 2019, 21, 1744-1752.	1.0	53
31	Temporal trends in intracerebral hemorrhage: Evidence from the Austrian Stroke Unit Registry. PLoS ONE, 2019, 14, e0225378.	1.1	3
32	Standards of practice in acute ischemic stroke intervention: International recommendations. Interventional Neuroradiology, 2019, 25, 31-37.	0.7	7
33	Cut stroke in half: Polypill for primary prevention in stroke. International Journal of Stroke, 2018, 13, 633-647.	2.9	29
34	ABCD3-I score and the risk of early or 3-month stroke recurrence in tissue- and time-based definitions of TIA and minor stroke. Journal of Neurology, 2018, 265, 530-534.	1.8	21
35	Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1995-2051.	6.3	294
36	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 2091-2138.	6.3	335

#	Article	IF	CITATIONS
37	Standards of Practice in Acute Ischemic Stroke Intervention: International Recommendations. American Journal of Neuroradiology, 2018, 39, E112-E117.	1.2	19
38	Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. New England Journal of Medicine, 2018, 379, 2429-2437.	13.9	959
39	Poststroke Neurocognitive Disorders Are Mostly Defined by Strategic Lesions. Stroke, 2018, 49, 2563-2564.	1.0	3
40	Standards of practice in acute ischemic stroke intervention: international recommendations. Journal of NeuroInterventional Surgery, 2018, 10, 1121-1126.	2.0	40
41	Stroke units around the world: the success story continues. Lancet, The, 2018, 391, 1970-1971.	6.3	2
42	Multidomain intervention for the prevention of cognitive decline after stroke – a pooled patientâ€ l evel data analysis. European Journal of Neurology, 2018, 25, 1182-1188.	1.7	16
43	Determining the feasibility and preliminary efficacy of a stroke instructional and educational DVD in a multinational context: a randomized controlled pilot study. Clinical Rehabilitation, 2018, 32, 1086-1097.	1.0	4
44	Cerebrolysin: a multi-target drug for recovery after stroke. Expert Review of Neurotherapeutics, 2018, 18, 681-687.	1.4	36
45	Systematic dysphagia screening and dietary modifications to reduce stroke-associated pneumonia rates in a stroke-unit. PLoS ONE, 2018, 13, e0192142.	1.1	36
46	Secondary stroke prevention offers now more choices and is critical to reduce the burden of recurrent stroke and death. Hamdan Medical Journal, 2018, 11, 1.	0.2	0
47	Prevention of stroke: Antihypertensives, cholesterol-lowering drugs, antithrombotics, anticoagulation, carotid surgery, and stenting. Hamdan Medical Journal, 2018, 11, 2.	0.2	0
48	Post-stroke dementia $\hat{a} \in $ a comprehensive review. BMC Medicine, 2017, 15, 11.	2.3	442
49	Do Women With Atrial Fibrillation Experience More Severe Strokes?. Stroke, 2017, 48, 778-780.	1.0	44
50	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 390, 231-266.	6.3	480
51	Overestimating the risk of aspiration in acute stroke. European Journal of Neurology, 2017, 24, e34.	1.7	1
52	Stroke doctors: Who are we? A World Stroke Organization survey. International Journal of Stroke, 2017, 12, 858-868.	2.9	15
53	Preventive effects of multiple domain interventions on lifestyle and risk factor changes in stroke survivors: Evidence from a two-year randomized trial. International Journal of Stroke, 2017, 12, 976-984.	2.9	14
54	Organizational Update. Stroke, 2017, 48, e341-e342.	1.0	8

#	Article	IF	CITATIONS
55	Patterns of Stroke Between University Hospitals and Nonuniversity Hospitals in Mainland China: Prospective Multicenter Hospital-Based Registry Study. World Neurosurgery, 2017, 98, 258-265.	0.7	45
56	Post-stroke pneumonia at the stroke unit – a registry based analysis of contributing and protective factors. BMC Neurology, 2016, 16, 107.	0.8	37
57	Clobal, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1775-1812.	6.3	740
58	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1603-1658.	6.3	1,612
59	Clobal, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Clobal Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	6.3	4,934
60	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1545-1602.	6.3	5,298
61	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1659-1724.	6.3	4,203
62	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1725-1774.	6.3	571
63	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1813-1850.	6.3	413
64	Predictive value of ABCD2 and ABCD3-I scores in TIA and minor stroke in the stroke unit setting. Neurology, 2016, 87, 861-869.	1.5	23
65	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. Lancet HIV,the, 2016, 3, e361-e387.	2.1	461
66	World Stroke Day 2016 – "Face the facts: Stroke is treatable― International Journal of Stroke, 2016, 11, 844-845.	2.9	1
67	Explanation and Elaboration of the Standards of Reporting of Neurological Disorders Checklist: A Guideline for the Reporting of Incidence and Prevalence Studies in Neuroepidemiology. Neuroepidemiology, 2015, 45, 113-137.	1.1	15
68	New Strategy to Reduce the Global Burden of Stroke. Stroke, 2015, 46, 1740-1747.	1.0	71
69	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 743-800.	6.3	4,951
70	The Stroke Riskometerâ,,¢ App: Validation of a Data Collection Tool and Stroke Risk Predictor. International Journal of Stroke, 2015, 10, 231-244.	2.9	103
71	Alteplase for Acute Ischemic Stroke. Stroke, 2015, 46, 746-756.	1.0	74
72	Multidomain Lifestyle Interventions for the Prevention of Cognitive Decline After Ischemic Stroke. Stroke, 2015, 46, 2874-2880.	1.0	56

#	Article	IF	CITATIONS
73	Development of the standards of reporting of neurological disorders (STROND) checklist: a guideline for the reporting of incidence and prevalence studies in neuroepidemiology. European Journal of Epidemiology, 2015, 30, 569-576.	2.5	35
74	Neuroprotection in ischemic stroke: what does the future hold?. Expert Review of Neurotherapeutics, 2015, 15, 227-229.	1.4	14
75	Prevention of Poststroke Cognitive Decline: ASPIS – a Multicenter, Randomized, Observer-Blind, Parallel Group Clinical Trial to Evaluate Multiple Lifestyle Interventions – Study Design and Baseline Characteristics. International Journal of Stroke, 2015, 10, 627-635.	2.9	14
76	IV thrombolysis in patients with ischemic stroke and alcohol abuse. Neurology, 2015, 85, 1592-1597.	1.5	13
77	Development of the Standards of Reporting of Neurological Disorders (STROND) checklist. Neurology, 2015, 85, 821-828.	1.5	57
78	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet, The, 2015, 386, 2145-2191.	6.3	1,544
79	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 2287-2323.	6.3	2,184
80	Postâ€stroke cognitive decline: an update and perspectives for clinical research. European Journal of Neurology, 2015, 22, 229.	1.7	184
81	Update on acute stroke therapy. Hamdan Medical Journal, 2015, 8, 315.	0.2	0
82	Experimental and Clinical Approaches to Recovery after Stroke. European Neurological Review, 2015, 10, 65.	0.5	0
83	Diabetes and thrombolysis for acute stroke: a clear benefit for diabetics. European Journal of Neurology, 2014, 21, 5-10.	1.7	17
84	Myocardial Infarction as a Complication in Acute Stroke: Results from the Austrian Stroke Unit Registry. Cerebrovascular Diseases, 2014, 37, 147-152.	0.8	30
85	Testing Devices for the Prevention and Treatment of Stroke and its Complications. International Journal of Stroke, 2014, 9, 683-695.	2.9	9
86	Report From the European Stroke Organization 2014. Stroke, 2014, 45, e188.	1.0	0
87	Diabetes and the brain: issues and unmet needs. Neurological Sciences, 2014, 35, 995-1001.	0.9	44
88	Second European Stroke Science Workshop. Stroke, 2014, 45, e113-22.	1.0	2
89	Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 1005-1070.	6.3	786
90	Evaluation of the Post Stroke Checklist: A Pilot Study in the United Kingdom and Singapore. International Journal of Stroke, 2014, 9, 76-84.	2.9	45

#	Article	IF	CITATIONS
91	Essential stroke services. World Stroke Academy, 2013, 1, 15-15.	0.1	Ο
92	Advances in Stroke. Stroke, 2013, 44, 311-313.	1.0	22
93	Stroke Care in Central Eastern Europe: Current Problems and Call for Action. International Journal of Stroke, 2013, 8, 365-371.	2.9	12
94	Development of a Poststroke Checklist to Standardize Follow-up Care for Stroke Survivors. Journal of Stroke and Cerebrovascular Diseases, 2013, 22, e173-e180.	0.7	84
95	World Stroke Academy Revamped. International Journal of Stroke, 2013, 8, 59-59.	2.9	2
96	Time Trends in Patient Characteristics Treated on Acute Stroke-Units. Stroke, 2013, 44, 1070-1074.	1.0	27
97	Use of intravenous recombinant tissue plasminogen activator in patients outside the defined criteria: safety and feasibility issues. Expert Review of Neurotherapeutics, 2013, 13, 177-185.	1.4	3
98	Poststroke spasticity. Neurology, 2013, 80, S1-4.	1.5	12
99	Toward an epidemiology of poststroke spasticity. Neurology, 2013, 80, S13-9.	1.5	245
100	Poststroke spasticity. Neurology, 2013, 80, S45-52.	1.5	216
101	WSO Stroke Education Program in Vietnam 2008–2011: 8596 Hospital Doctors Attended in 58 Cities and Received a Certificate from the WSO and the Ministry of Health. International Journal of Stroke, 2013, 8, 148-149.	2.9	2
102	Psychosocial Distress, an Underinvestigated Risk Factor for Stroke. Stroke, 2013, 44, 305-306.	1.0	11
103	European Stroke Organisation. Stroke, 2013, 44, .	1.0	3
104	Cerebrolysin in Patients With Acute Ischemic Stroke in Asia. Stroke, 2012, 43, 630-636.	1.0	115
105	Poststroke Chronic Disease Management: Towards Improved Identification and Interventions for Poststroke Spasticity-Related Complications. International Journal of Stroke, 2011, 6, 42-46.	2.9	94
106	Stroke: Working toward a Prioritized World Agenda. International Journal of Stroke, 2010, 5, 238-256.	2.9	89
107	Stroke: Working toward a Prioritized World Agenda. Cerebrovascular Diseases, 2010, 30, 127-147.	0.8	25
108	Stroke: Working Toward a Prioritized World Agenda. Stroke, 2010, 41, 1084-1099.	1.0	122

#	Article	IF	CITATIONS
109	European Stroke Facilities Survey: The German and Austrian Perspective. Cerebrovascular Diseases, 2009, 27, 138-145.	0.8	34
110	Editorial: Stroke Units in Austria: structure, performance and results. Wiener Medizinische Wochenschrift, 2008, 158, 407-410.	0.5	8
111	Dysphagia Bedside Screening for Acute-Stroke Patients. Stroke, 2007, 38, 2948-2952.	1.0	428
112	The 1st International Conference on Advancement and Recommendations for Stroke Management (ICARSM) Held in Chengdu, China. International Journal of Stroke, 2007, 2, 231-231.	2.9	3
113	Acute treatment and long-term management of stroke in developing countries. Lancet Neurology, The, 2007, 6, 553-561.	4.9	146
114	Organization of Stroke Care: Education, Referral, Emergency Management and Imaging, Stroke Units and Rehabilitation. Cerebrovascular Diseases, 2004, 17, 1-14.	0.8	58
115	Stroke emergency: Evidence favours laying the patient on the paretic side. Wiener Medizinische Wochenschrift, 2004, 154, 568-570.	0.5	1
116	Acute Stroke Units in Austria Are Being Set Up on a National Level Following Evidence-Based Recommendations and Structural Quality Criteria. Cerebrovascular Diseases, 2003, 15, 29-32.	0.8	25
117	Silent Brain Infarcts and Transient Ischemic Attacks. Stroke, 1995, 26, 1348-1352.	1.0	38

Imaging for prediction of functional outcome and for assessment of recovery. , 0, , 64-81.